Literature DB >> 7527301

Anti-(glioma surface antigen) monoclonal antibody G-22 recognizes overexpressed CD44 in glioma cells.

H Okada1, J Yoshida, H Seo, T Wakabayashi, K Sugita, M Hagiwara.   

Abstract

We raised an anti-glioma monoclonal antibody, named G-22, that specifically recognizes a human glioma-associated surface antigen. Proven to be useful for target imaging of malignant gliomas after radioisotope labeling and cerebrospinal fluid diagnosis by enzyme-linked immunospecific assay, G-22 was found to immunoprecipitate an 85-kDa glycoprotein of the human glioma U-251MG cell. We purified this antigen by G-22-coupled cyanogenbromide-activated Sepharose affinity chromatography, and sequence analysis demonstrated that the 54 amino acid residues were identical to positions 55-108 of human CD44. The results show that the smallest spliced form (85 kDa) of CD44 is strongly expressed in glioma cells.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7527301     DOI： 10.1007/bf01519984

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN： 0340-7004            Impact factor:   6.968


  15 in total

1.  Multiple variants of the human lymphocyte homing receptor CD44 generated by insertions at a single site in the extracellular domain.

Authors:  D G Jackson; J Buckley; J I Bell
Journal:  J Biol Chem       Date:  1992-03-05       Impact factor: 5.157

Review 2.  CD44 splice variants: metastases meet lymphocytes.

Authors:  P Herrlich; M Zöller; S T Pals; H Ponta
Journal:  Immunol Today       Date:  1993-08

3.  Radioimmunoassay of glioma-associated antigen in cerebrospinal fluid and its usefulness for the diagnosis and monitoring of human glioma.

Authors:  J Yoshida; R Yamamoto; T Wakabayashi; M Nagata; H Seo
Journal:  J Neurooncol       Date:  1990-02       Impact factor: 4.130

4.  A human lymphocyte homing receptor, the hermes antigen, is related to cartilage proteoglycan core and link proteins.

Authors:  L A Goldstein; D F Zhou; L J Picker; C N Minty; R F Bargatze; J F Ding; E C Butcher
Journal:  Cell       Date:  1989-03-24       Impact factor: 41.582

5.  Characterization of neuroectodermal antigen by a monoclonal antibody and its application in CSF diagnosis of human glioma.

Authors:  T Wakabayashi; J Yoshida; H Seo; K Kazo; Y Murata; N Matsui; N Kageyama
Journal:  J Neurosurg       Date:  1988-03       Impact factor: 5.115

6.  A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells.

Authors:  U Günthert; M Hofmann; W Rudy; S Reber; M Zöller; I Haussmann; S Matzku; A Wenzel; H Ponta; P Herrlich
Journal:  Cell       Date:  1991-04-05       Impact factor: 41.582

7.  Radioimaging of human glioma xenografts with 123I labeled monoclonal antibody G-22 against glioma-associated antigen.

Authors:  J Yoshida; M Mizuno; I Inoue; T Wakabayasi; K Sugita; H Seo; K Chiba
Journal:  J Neurooncol       Date:  1990-06       Impact factor: 4.130

8.  Variant CD44 adhesion molecules are expressed in human brain metastases but not in glioblastomas.

Authors:  H Li; M F Hamou; N de Tribolet; R Jaufeerally; M Hofmann; A C Diserens; E G Van Meir
Journal:  Cancer Res       Date:  1993-11-15       Impact factor: 12.701

9.  Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons.

Authors:  G R Screaton; M V Bell; D G Jackson; F B Cornelis; U Gerth; J I Bell
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

10.  The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells.

Authors:  I Stamenkovic; A Aruffo; M Amiot; B Seed
Journal:  EMBO J       Date:  1991-02       Impact factor: 11.598
View more
  3 in total

Review 1.  Circulating glioma biomarkers.

Authors:  Johan M Kros; Dana M Mustafa; Lennard J M Dekker; Peter A E Sillevis Smitt; Theo M Luider; Ping-Pin Zheng
Journal:  Neuro Oncol       Date:  2014-09-24       Impact factor: 12.300

2.  Hyaluronate receptors mediating glioma cell migration and proliferation.

Authors:  Y Akiyama; S Jung; B Salhia; S Lee; S Hubbard; M Taylor; T Mainprize; K Akaishi; W van Furth; J T Rutka
Journal:  J Neurooncol       Date:  2001-06       Impact factor: 4.130

3.  Monoclonal antibody ONS-M21 recognizes integrin alpha3 in gliomas and medulloblastomas.

Authors:  H Kishima; K Shimizu; K Tamura; Y Miyao; E Mabuchi; E Tominaga; J Matsuzaki; T Hayakawa
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.